Qi Kang Medical Technology (Changzhou) Co., Ltd. announced that it has received ?20 million in an equity round of funding from returning investor Yantai Dongcheng Pharmaceutical Group Co.,Ltd. on November 14, 2023. The investor subsequently holds 50% of the shares of the company. The shares are issued by way capital increase.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.05 CNY | +3.43% | -1.71% | -34.26% |
27/05 | Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug | MT |
20/05 | Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.26% | 1.37B | |
+24.53% | 45.07B | |
+30.99% | 23.39B | |
+24.13% | 16.08B | |
+21.15% | 14.6B | |
+68.67% | 14.01B | |
-0.05% | 6.79B | |
-13.29% | 6.38B | |
-8.87% | 5.73B | |
+13.53% | 5.64B |
- Stock Market
- Equities
- 002675 Stock
- News Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
- Qi Kang Medical Technology Co., Ltd. announced that it has received ?20 million in funding from Yantai Dongcheng Pharmaceutical Group Co.,Ltd.